Generic Drugmaker Sees Obstacles to Copying Advair Before 2018Generic Drugmaker Sees Obstacles to Copying Advair Before 2018

Teva Pharmaceuticals does not expect to see the launch of generic copies of GlaxoSmithKline's best-selling drug Advair (fluticasone/salmeterol) that could be sold as a true substitute to U.S. patients before 2018. Reuters Health Information

Source: Medscape Medical News Headlines - October 8, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news